Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 14/20 | 0.78 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31130222 | 0.88 | HCAR3 (0.60) | HCAR3SLC9A1MAPTKMONPC1 | |
| SCHEMBL6044058 | 0.88 | HCAR3 (1.00) | HCAR3HPGDHCAR2MAPT | |
| SCHEMBL6184141 | 0.84 | HCAR3 (0.56) | HCAR3SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL14106775 | 0.81 | HCAR3 (0.53) | HCAR3PLA2G4ASLC9A1MAPTMEN1 | |
| SCHEMBL1256199 | 0.79 | HCAR3 (0.76) | HCAR3HPGDHCAR2MAPTMEN1 | |
| SCHEMBL31130343 | 0.78 | HCAR3 (0.50) | HCAR3SLC9A1MAPTNPC1RAB9A | |
| SCHEMBL29022082 | 0.78 | HCAR3 (0.80) | HCAR3SLC9A1MAPTNPC1RAB9A | |
| SCHEMBL2852713 | 0.77 | HSD17B10 (0.56) | HCAR3HPGDHCAR2 | |
| SCHEMBL6184550 | 0.76 | HCAR3 (0.80) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044508 | 0.76 | HCAR3 (1.00) | HCAR3PLA2G4ASLC9A1HPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | HCAR3 495/4885PLA2G4A 3799/4885SLC9A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.